Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Actemra Scores New Indication In Rare Autoimmune Disease

SSc-ILD Indication Comes With Biosimilar Competition On The Horizon

Executive Summary

The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.

You may also be interested in...



Coronavirus Update: At One-Year Mark, WHO Stresses Importance Of Fair Vaccine Distribution

Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.

Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025

Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).

More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?

The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel